PNC Financial Services Group’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$224K Sell
7,257
-320
-4% -$7.91K ﹤0.01% 2386
2026
Q1
$164K Buy
7,577
+316
+4% +$6.83K ﹤0.01% 2466
2025
Q4
$173K Sell
7,261
-333
-4% -$6.79K ﹤0.01% 2407
2025
Q3
$103K Sell
7,594
-3
-0% -$31 ﹤0.01% 2780
2025
Q2
$61.8K Buy
7,597
+6,191
+440% +$52.9K ﹤0.01% 2993
2025
Q1
$11K Buy
1,406
+511
+57% +$5.92K ﹤0.01% 3793
2024
Q4
$13.3K Sell
895
-970
-52% -$15.8K ﹤0.01% 3695
2024
Q3
$28.5K Sell
1,865
-852
-31% -$13.4K ﹤0.01% 3345
2024
Q2
$41.4K Buy
2,717
+740
+37% +$11.9K ﹤0.01% 3124
2024
Q1
$37.3K Buy
1,977
+470
+31% +$8.13K ﹤0.01% 3123
2023
Q4
$28.8K Sell
1,507
-2,394
-61% -$38.3K ﹤0.01% 3242
2023
Q3
$70K Buy
3,901
+422
+12% +$8.48K ﹤0.01% 2774
2023
Q2
$70.7K Buy
3,479
+1,521
+78% +$29K ﹤0.01% 2842
2023
Q1
$35.7K Sell
1,958
-873
-31% -$16.7K ﹤0.01% 3167
2022
Q4
$58.5K Buy
2,831
+279
+11% +$7.68K ﹤0.01% 2885
2022
Q3
$67K Buy
2,552
+888
+53% +$23.5K ﹤0.01% 2790
2022
Q2
$42K Buy
+1,664
New +$40.8K ﹤0.01% 3103

Other funds holding RCUS

PNC Financial Services Group's RCUS Position: Q2 2026 in Review

PNC Financial Services Group reduced its Arcus Biosciences (RCUS) stake by 4.2% in Q2 2026, selling an estimated $7.91K and leaving 7,257 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

PNC Financial Services Group first reported a position in RCUS in Q2 2022 and has held it in 17 quarters since. 95 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • PNC Financial Services Group held 7,257 shares of Arcus Biosciences worth $224K as of Q2 2026.
  • PNC Financial Services Group sold 320 Arcus Biosciences shares in Q2 2026, an estimated $7.91K.
  • Arcus Biosciences made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2386 holding.
  • PNC Financial Services Group first reported a position in Arcus Biosciences in Q2 2022 and has held it in 17 quarters since.
  • 95 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.